Mobile Menu - OpenMobile Menu - Closed

Hearing on "Examining FDA’s Generic Drug and Biosimilar User Fee Programs," Subcommittee on Health (March 2, 2017)

Date: 
Thursday, March 2, 2017 - 10:00am
Location: 
2123 Rayburn House Office Building

The Subcommittee on Health will hold a hearing on Thursday, March 2, 2017, at 10:00 a.m. in 2123 Rayburn House Office Building.  The hearing is entitled “Examining FDA’s Generic Drug and Biosimilar User Fee Programs.”  

 

Livestream

 

Key Documents

Memorandum from Ranking Member Pallone to the Subcommittee on Health

Opening Statement of Ranking Member Pallone as prepared for delivery

 

Witnesses

Panel I

Janet Woodcock, M.D.
Director, Center for Drug Evaluation and Research
U.S. Food and Drug Administration
 
Panel II
 
David Gaugh
Senior Vice President of Sciences and Regulatory Sciences
Association for Accessible Medicines
 
Bruce A. Leicher
Senior Vice President and General Counsel
Momenta Pharmaceuticals, Inc.
Chair, The Biosimilars Council, a Division of the Association for Accessible Medicines
 
Juliana Reed
Vice President of Government Affairs
Coherus BioSciences
Immediate Past President, The Biosimilars Forum
 
Kay Holcombe
Senior Vice President of Science Policy
Biotechnology Industry Organization
 
Allan Coukell
Senior Director, Health Programs
The Pew Charitable Trusts
 
Issues: